Pathogen-fighting immune cells called tissue-resident memory CD8 T cells (TRM cells) go through a surprising transformation -- and relocation -- as they fight infections in the small intestine.

To confirm that protein transfer isn’t limited to cultured cells, the team injected cancer cells into a ... The findings suggest that transfer of THY1 from CAF to endothelial cells helps immune cells ...

CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving outcomes in hematological malignancies.

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

Discover how a new study highlights the transformative potential of Th2 immunity in early cancer intervention.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...

An injectable hydrogel platform shows promise in local immunotherapy for triple-negative breast cancer, enhancing treatment ...

Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

For the first time, researchers have used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

ERNA-101 cells were detected in the tumor after 42 days. Relative to the control groups, the ERNA-101 group exhibited substantially higher T cell infiltration and reduced tumor size. Additionally ...